Insulin Delivery Devices Market Insights | Key players Becton, Dickinson and Company, Novo Nordisk A/S , Ypsomed Holding AG , Medtronic plc , Animas Corporation , Tandem Diabetes Care, Inc., Sanofi , Biocon Ltd. , Eli Lilly and Company , and Insulet Corpo

The report "Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021", analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Browse 100 market data tables and 38 figures spread through 149 pages and in-depth TOC on "Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021"

http://www.marketsandmarkets.com/Market-Reports/insulin-delivery-device-market-107632092.html?utm_source=OpenPR&utm_medium=Paid

Early buyers will receive 10% customization on reports.
This report studies the global insulin delivery devicesmarket for the forecast period of 2016 to 2021. This market is expected to reach USD 17.85 Billion by 2021 from USD 11.54 Billion in 2016, growing at a CAGR of 9.1%.

The global insulin delivery devices market is segmented on the basis of type, end user, and region.

Download PDF Brochure: - http://www.marketsandmarkets.com/pdfdownload.asp?id=107632092&utm_source=OpenPR&utm_medium=Paid

On the basis of type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and other devices (inhalers, transdermal patches, and jet injectors). In 2016, the insulin pens segment commanded the largest share of the insulin delivery devices market. The insulin pens segment is further divided into reusable and disposable pens. The reusable pens segment commanded the largest share of the insulin pens market in 2016. This large share can be attributed to its lower price compared to disposable pens, availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region. However, the insulin pumps segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the increasing prevalence of Type 1 diabetes and technological advancements in insulin pumps.

On the basis of end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment commanded the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure.

Speak to Analyst: - http://www.marketsandmarkets.com/speaktoanalyst.asp?id=107632092&utm_source=OpenPR&utm_medium=Paid

On the basis of region, North America accounted for the largest share of the global insulin delivery devices market in 2016. In the coming years, the insulin delivery devices market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in the region can be attributed to the rising partnerships among the global and local players in Asia-Pacific countries. Moreover, high adoption of insulin pens and approvals for injectable insulin in Japan, increasing government initiatives in Singapore, and amendments in NDSS to broaden patient access to diabetes products in Australia are expected to support the growth of the Asia-Pacific insulin delivery devices market.

Key players in the global insulin delivery devices market include Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (U.S.), Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

This release was published on openPR.